ZNF566-AS1: A Potential Drug Target and Biomarker (G728752)
ZNF566-AS1: A Potential Drug Target and Biomarker
ZNF566-AS1, also known as ZNF566 antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. ZNF566-AS1 is a key regulator of the T-cell receptor (TCR), a critical immune cell receptor that plays a crucial role in fighting off infections and diseases. T-cell receptor signaling is also associated with various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.
The ZNF566-AS1 Molecule
ZNF566-AS1 is a small non-coding RNA molecule that consists of approximately 1,200 amino acid residues. It is expressed in various tissues and cells, including T cells, B cells, immune cells, and cancer cells. ZNF566-AS1 is primarily localized to the cytoplasm of these cells and can interact with various cellular signaling pathways, including the T-cell receptor signaling pathway.
The T-cell receptor is a transmembrane protein that is composed of a variable region and a constant region. The variable region of the T-cell receptor contains the T-cell receptor alpha chain, which consists of the entire extracellular domain of the receptor. The constant region of the T-cell receptor contains various regulatory elements, including a nuclear receptor-inserted gene (ROR) that encodes the RNA molecule ZNF566-AS1.
The ZNF566-AS1-ROR Interaction
ZNF566-AS1 has been shown to interact with the T-cell receptor alpha chain in various ways. Firstly, ZNF566-AS1 can bind to the ROR protein, which is a key regulator of the T-cell receptor alpha chain. This interaction between ZNF566-AS1 and ROR has been shown to play a role in regulating the activity of the T-cell receptor alpha chain.
Secondly, ZNF566-AS1 can also interact with the T-cell receptor alpha chain through a process called RNA-protein interactions. This interaction between ZNF566-AS1 and the T-cell receptor alpha chain allows for the regulation of the activity of the T-cell receptor alpha chain at the post-transcriptional level.
Potential Drug Target
The ZNF566-AS1 molecule has been identified as a potential drug target due to its involvement in the T-cell receptor signaling pathway. Several studies have shown that inhibition of ZNF566-AS1 can lead to decreased activity of the T-cell receptor alpha chain, which can result in a variety of cellular responses, including decreased proliferation, increased apoptosis, and decreased survival rates.
One potential drug that has been shown to interact with ZNF566-AS1 is the small molecule inhibitor, 2-fluoro-4-methoxybenzaldehyde (FMBA). FMBA is a potent inhibitor of the T-cell receptor alpha chain and has been shown to reduce the activity of the T-cell receptor alpha chain in cell culture and animal models of disease.
Another potential drug that may interact with ZNF566-AS1 is the mTOR inhibitor, rapamycin. Rapamycin is an inhibitor of the mTOR signaling pathway, which is a critical pathway involved in cell growth, metabolism, and survival. The mTOR signaling pathway is closely related to the T-cell receptor signaling pathway, and therefore, inhibition of the mTOR signaling pathway may also inhibit the activity of the T-cell receptor alpha chain.
Biomarker Potential
ZNF566-AS1 has also been identified as a potential biomarker for a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. The T-cell receptor is a critical immune cell receptor that is involved in fighting off
Protein Name: ZNF566 Antisense RNA 1
The "ZNF566-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF566-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF567 | ZNF568 | ZNF569 | ZNF56P | ZNF57 | ZNF570 | ZNF571 | ZNF571-AS1 | ZNF572 | ZNF573 | ZNF574 | ZNF575 | ZNF576 | ZNF577 | ZNF578 | ZNF579 | ZNF580 | ZNF582 | ZNF582-DT | ZNF583 | ZNF584 | ZNF585A | ZNF585B | ZNF586 | ZNF587 | ZNF587B | ZNF589 | ZNF592 | ZNF593 | ZNF594 | ZNF594-DT | ZNF595 | ZNF596 | ZNF597 | ZNF598 | ZNF599 | ZNF600 | ZNF603P | ZNF605 | ZNF606 | ZNF607 | ZNF608 | ZNF609 | ZNF610 | ZNF611 | ZNF613 | ZNF614 | ZNF615 | ZNF616 | ZNF618 | ZNF619 | ZNF620 | ZNF621 | ZNF622 | ZNF623 | ZNF624 | ZNF625 | ZNF625-ZNF20 | ZNF626 | ZNF627 | ZNF628 | ZNF629 | ZNF630 | ZNF638 | ZNF639 | ZNF641 | ZNF644 | ZNF646 | ZNF648 | ZNF649 | ZNF652 | ZNF652-AS1 | ZNF653 | ZNF654 | ZNF655 | ZNF658 | ZNF658B | ZNF66 | ZNF660 | ZNF662 | ZNF663P | ZNF664 | ZNF664-RFLNA | ZNF665 | ZNF667 | ZNF667-AS1 | ZNF668 | ZNF669 | ZNF670 | ZNF670-ZNF695 | ZNF671 | ZNF672 | ZNF674 | ZNF674-AS1 | ZNF675 | ZNF676 | ZNF677 | ZNF678 | ZNF679 | ZNF680
